11 patents
Utility
Inhibitors of menin-mll interaction
19 Dec 23
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins.
Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
Filed: 10 Sep 21
Utility
Irreversible Inhibitors of Menin-mll Interaction
7 Dec 23
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins.
Thomas BUTLER, Jim PALMER, Ravi UPASANI, Matthew WELSCH, Sridhar VEMPATI, Brendan KELLY, Edward PAINTER
Filed: 31 Jul 23
Utility
Pyrazine Compounds As Inhibitors of FLT3
26 Oct 23
Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3.
David Sperandio, Xiaodong Wang, Thorsten A. Kirschberg, James T. Palmer, Thomas Butler, Solomon B. Ungashe, Neil Howard Squires, Nan-Horng Lin, Ravindra B. Upasani, Amna Trinity-Turjuman Adam, Yongli Su, Thu Phan
Filed: 29 Dec 22
Utility
Irreversible Inhibitors of Menin-mll Interaction
20 Jul 23
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins.
Thomas BUTLER, Jim PALMER, Ravi UPASANI, Matthew WELSCH, Sridhar VEMPATI, Brendan KELLY, Edward PAINTER
Filed: 9 Jan 23
Utility
Substituted pyridines as irreversible inhibitors of menin-MLL interaction
18 Jul 23
Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
Filed: 18 Jun 21
Utility
Covalent Inhibitors of Menin-mll Interaction for Diabetes Mellitus
20 Apr 23
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins for the treatment of diabetes mellitus.
Thomas BUTLER, James T. PALMER
Filed: 10 Aug 22
Utility
Crystalline Forms of an Irreversible Inhibitor of Menin-mll Interaction
23 Mar 23
Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, including crystalline forms, solvates, and pharmaceutically acceptable salts thereof.
Priaynka SOMANATH, Daniel LU, Taisei KINOSHITA, Brian LAW, Thomas BUTLER, James T. PALMER, Nan-Horng LIN, Heow Meng TAN, Angelina Sau Man WONG, Siyi JAING, Hongyan HE
Filed: 10 Aug 22
Utility
Irreversible Inhibitors of Menin-mll Interaction
2 Jun 22
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins.
Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
Filed: 18 Jun 21
Utility
Inhibitors of Menin-mll Interaction
27 Jan 22
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins.
Thomas BUTLER, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
Filed: 10 Sep 21
Utility
Inhibitors of menin-MLL interaction
16 Nov 21
Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
Filed: 31 Dec 19
Utility
Substituted pyridines as irreversible inhibitors of menin-MLL interaction
10 Aug 21
Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
Filed: 31 Dec 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first